Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results
from two Phase 3 studies of lumacaftor in combination with ivacaftor
that showed statistically significant improvements in lung function
(percent predicted forced expiratory volume in one second, or ppFEV 1 )
in people ages 12 and older with cystic fibrosis (CF) who have two
copies (homozygous) of the F508del mutation in the cystic fibrosis
transmembrane conductance regulator ( CFTR ) gene.
for Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation investment picks